Condition: Urothelial Carcinoma · Sponsor: Pacific Edge Limited
It is currently debated whether the use of invasive standard of care procedures, such as cystoscopy, a procedure which involves inserting a thin camera, called a cystoscope, into the bladder to look for signs of disease, is appropriate for patients with microscopic hematuria (blood in the urine that cannot be seen with the naked eye). This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low in this population group, approximately 3%. Invasive procedures such as cystoscopy can cause anxiety and pain, in addition to other potential side effects. This has resulted in low admittance for cystoscopy among patients with hematuria (blood in urine) in urology clinics. Therefore, there is a need for a simpler, non-invasive test that can accurately detect the presence or absence of disease (urothelial carcinoma) in patients with microscopic hematuria. Cxbladder, a non-invasive, urine-based test, has the potential to fill this role.
This description comes directly from the study's public registry record.
Ash Maharjan, PhD · +64 27 318 0613 · ash.maharjan@pelnz.com
Alexis White, BSc (Hons) · +64 21 959 001 · alexis.white@pelnz.com
Always discuss trial participation with your own doctor first.
| Tri Valley Urology Medical Group | Murrieta, California, United States | Recruiting |
| AccuMed Research Associates | Garden City, New York, United States | Recruiting |
| Durham VA Health Care System | Durham, North Carolina, United States | Recruiting |
| The Urology Place | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05889195